Anti-PD-L1 Antibody-drug Conjugate HLX43 clinical trials
Also written HLX43.
Its developmentBy Fosun Pharma, step by step17 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-PD-L1 Antibody-drug Conjugate HLX43 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-PD-L1 Antibody-drug Conjugate HLX43 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2025 (10)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 10 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 9
Studies that test Anti-PD-L1 Antibody-drug Conjugate HLX43.
- Nov 2026A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyPhase 2 · Shanghai Henlius Biotech
- Dec 2026A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid TumorsPhase 1 · Shanghai Henlius Biotech
- Dec 2026A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast CancerPhase 2 · Shanghai Henlius Biotech
- Dec 2026Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal CancerPhase 2 · Shanghai Henlius Biotech
- Dec 2026A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant TumorsPhase 2 · Shanghai Henlius Biotech
- May 2027Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.Phase 2 · Shanghai Henlius Biotech
- Jun 2027A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung CancerPhase 2 · Shanghai Henlius Biotech
- Jul 2027A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal CancerPhase 1/2 · Shanghai Henlius Biotech
- Aug 2027Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction AdenocarcinomaPhase 2 · Shanghai Henlius Biotech
Studies
Open first, then newest update. How each study uses Anti-PD-L1 Antibody-drug Conjugate HLX43 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid TumorsEnrolling by invitationPhase 1Shanghai Henlius BiotechNCT06115642Written as HLX43How we know
- A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 2Shanghai Henlius BiotechNCT06907615Written as HLX43 DOSE 1 (2.0 mg/kg)How we know
- A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung CancerRecruitingPhase 2Shanghai Henlius BiotechNCT07253142Written as HLX43 dose 1How we know
- A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCRecruitingPhase 2Shanghai Henlius BiotechNCT07269782Written as HLX43 DOSE 1How we know
- A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung CancerRecruitingPhase 2/3Shanghai Henlius BiotechNCT07459751Written as HLX43How we know
- A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard TherapyRecruitingPhase 2Shanghai Henlius BiotechNCT06769113Written as HLX43How we know
- A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant TumorsRecruitingPhase 2Shanghai Henlius BiotechNCT06769152Written as HLX43How we know
- Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.Not yet recruitingPhase 2Shanghai Henlius BiotechNCT07487519Written as HLX43 DOSE 1 IN ≥2L TNBCHow we know
- A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast CancerNot yet recruitingPhase 2Shanghai Henlius BiotechNCT07459738Written as HLX43How we know
- A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Shanghai Henlius BiotechNCT06857279Written as HLX43 DOSE 1How we know
- A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal CancerNot yet recruitingPhase 1/2Shanghai Henlius BiotechNCT07358585Written as HLX43 dose 1 + HLX07How we know
- A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic CancerNot yet recruitingPhase 2Shanghai Henlius BiotechNCT07301229Written as HLX43 DOSE 1 (2.5 mg/kg)How we know
- A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingPhase 2Shanghai Henlius BiotechNCT06839066Written as HLX43 DOSE 1How we know
- Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2Shanghai Henlius BiotechNCT07115485Written as HLX43 DOSE 1How we know
- A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid TumorsRecruitingPhase 1/2Shanghai Henlius BiotechNCT06848699Written as HLX43 dose 1How we know
- Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal CancerRecruitingPhase 2Shanghai Henlius BiotechNCT07106892Written as HLX43 Dose 1;How we know
- A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard TherapyRecruitingPhase 2Shanghai Henlius BiotechNCT06742892Written as HLX43 DOSE 1How we know